INTRODUCTION
Sulfasalazine has been used effectively in the treatment of ulcerative colitis but its mechanism of action is unknown. Prostaglandins are importarlt mediators of inflammation; elevated levels of prostaglandins have been found in the stool and blood of patients with ulcerative colitis and elevated levels of prostaglandin metabolites have been found in their urine (1) . Organ cultures of rectal biopsies from these patients secrete increased amounts of prostaglandins (2) . Treatment of ulcerative colitis patients with sulfasalazine results in decreased levels of prostaglandins in the stool and blood, and decreased levels of prostaglandin metabolites in the urine (1) . These findings have led to the hypothesis that prostaglandins are major mediators of inflammation in ulcerative colitis and that sulfasalazine reduces inflammation by blocking prostaglandin synthesis (1, 2) . A major argument against this hypothesis is that other drugs that inhibit prostaglandin synthesis are not useful in the treatment of ulcerative These studies were presented at the Midwest Regional Meeting of the American Federation for Clinical Research, Chicago, Ill., November, 1981. Received for publication 6 November 1981. colitis. Indomethacin, for example, blocks cyclooxygenase and reduces prostaglandin levels in the stool of patients with ulcerative colitis and also reduces the levels of prostaglandin metabolites in their urine; but indomethacin is totally ineffective (1) . The pathology of ulcerative colitis is remarkable for the accumulation of large numbers of neutrophils and other inflammatory cells in the colonic mucosa. Neutrophils metabolize arachidonic acid to prostaglandin E2 (PGE2)' and thromboxane B2 through the cyclooxygenase pathway, but their major arachidonate metabolites are the lipoxygenase products 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) and 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid (5,12 di-HETE) also known as leukotriene B4 (3, 4). 5-HETE and 5,12 diHETE are chemotactic agents; they are thought to have an important role in recruiting neutrophils into areas of inflammation (5, 6) . Neutrophils metabolize arachidonate through the lipoxygenase pathway when stimulated with the ionophore A23187, or the chemotactic peptide formylmethionylleucylphenylalanine (3, 7) . We have used ionophore-stimulated neutrophils as a test system because ionophore is the most potent stimulus of the lipoxygenase pathway in neutrophils. In this study we demonstrate that sulfasalazine and one of its metabolites, 5-aminosalicylate, block the synthesis of 5-HETE and 5,12 di-HETE by human neutrophils. We suggest that the efficacy of sulfasalazine in the treatment of ulcerative colitis may relate to the inhibition of the synthesis of these chemotactic compounds.
METHODS
Purification of cells. Healthy volunteer blood donors gave written consent to participate in this study, which was 'Abbreviations used in this paper: 5-HETE, 5-hydroxy-6,8,11,14-eicosatetraenoic acid; 5,12 diHETE, 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid; PGE2, prostaglandin E2; TLC, thin-layer chromatography.
approved by the Washington University Human Studies Committee. Purified neutrophils were prepared from heparinized blood by dextran sedimentation followed by isopycnic centrifugation using a Ficoll-Hypaque gradient (Pharmacia Fine Chemicals, Div. Pharmacia, Inc., Piscataway, N. J.). Blood donors had taken no medication for at least 2 wk. Neutrophil preparations were monitored by phase microscopy and Giemsa staining and contained less than one platelet per neutrophil. More than 98% of the nucleated cells were neutrophils.
Incubation conditions. Neutrophils were suspended in buffer (NaCl 100 mM, Tris HCI 50 mM pH 7.4, glucose 1 mg/ml, CaC12 1 mM) and incubated in the presence or absence of inhibitors for 10 min at 370 in a volume of 1 ml and at a cell concentration of 1 X 107/ml. After arachidonic acid were separated by thin-layer chromatography (TLC) and identified by autoradiography and comigration with known standards. The TLC solvent system used was benzene/ether/ethanol/acetic acid (50:40:2:0.2). The radioactive areas on the TLC plates detected by autoradiography were scraped, and the radioactivity measured in a liquid scintillation counter. The results are expressed as percentage of total recovered radioactivity found in each product. Percent inhibition is defined as:
% total radioactivity in a product in the presence of the inhibitor % total radioactivity in a product in the absence of the inhibitor Reagents. Sulfasalazine, sulfapyridine, and 5-aminosalicylate were gifts of Pharmacia, Inc. Sulfapyridine and sulfasalazine were dissolved in small volumes of 0.1 N NaOH, diluted with buffer and the pH adjusted to 7.4. 5, 12 diHETE were biosynthesized and identified by TLC, highpressure liquid chromatography, ultraviolet absorbance, and gas chromatography-mass spectroscopy as described previously (3, 8) .
RESULTS
Human peripheral blood neutrophils stimulated with the ionophore A23187 metabolize exogenous arachidonate through the lipoxygenase pathway to 5-HETE (4.0%) and 5,12 diHETE (6.4%) ( Table I) . A significant portion of the exogenous arachidonate is esterified into phospholipids (20.6%) and triglycerides (19.0%).
Sulfasalazine inhibits the synthesis of 5-HETE and 5,12 diHETE in a similar fashion. The 50% inhibitory dose (ID50) for the inhibition of 5,12 diHETE synthesis is 0.9 mM, for 5-HETE it is 1.5 mM (Fig. 1 ) At sulfasalazine concentrations >4 mM there is almost 100% inhibition of synthesis of both products. 5-Aminosalicylate inhibits 5,12 diHETE with an ID50 of 4 mM, although inhibition was not complete even at concentrations as high as 16 mM. 5-Aminosalicylate was ineffective in blocking 5-HETE production. Sulfapyridine caused partial inhibition of the synthesis of both compounds, reaching a maximum of 30% inhibition at 4-6 mM. There was no cytotoxicity, as determined by trypan blue exclusion, in any of the conditions tested. Using the same test system indomethacin at concentrations up to 50 ,uM did not inhibit the synthesis of 5-HETE or 5,12 diHETE (data not shown).
DISCUSSION
In this study we have demonstrated that sulfasalazine inhibits the synthesis of 5-HETE and 5,12 diHETE by human neutrophils. The sulfasalazine metabolite 5-aminosalicylate also inhibits the synthesis of 5,12 diHETE. The ID50 for sulfasalazine is 0.9-1.5 mM (36-60 mg/100 ml), which is less than the average concentration of sulfasalazine in the stool of treated patients (78 mg/100 ml) (9) . The ID50 for the inhibition of 5,12 diHETE synthesis by 5-aminosalicylate is 5 mM (75 mg/ 100 ml), which is also less than the average concentration in the stool (150 mg/100 ml) (9). Sulfapyridine was least effective in inhibiting the synthesis of these compounds. The lesser inhibitory activ- urine of these patients (1) . In this study we have shown that sulfasalazine and h substantially lower its metabolite, 5-aminosalicylate, block the synthesis ml) (9), make it un-of products of the lipoxygenase pathway, products that armacologically im-have important roles in recruiting inflammatory cells Previous studies de-into sites of inflammation. We suggest that the inhieutic component of bition of the synthesis of 5-HETE and 5,12 diHETE ts treated with either accounts for some of the antiinflammatory effects of te alone improved, sulfasalazine seen in ulcerative colitis.
idine did not (10) . ' 
